Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Nyxoah (NYXH) appointed Liam Kelly chief executive officer effective October 1, 2026, succeeding Olivier Taelman.
Nyxoah links the change to its shift toward U.S.-focused commercialization following FDA approval and the U.S. launch of its Genio sleep apnea treatment. Kelly served as president and CEO of Teleflex (TFX) from January 2018 until January 2026 and as its chairman from May 2020 until January 2026. He is also a director of Enovis (ENOV).
Enovis (ENOV) has expanded its support of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.
In addition to its longstanding sponsorship of the American Joint Replacement Registry (AJRR), Enovis will now support the Shoulder & Elbow Registry (SER) through 2027. The SER focuses on shoulder and elbow care, an area where nearly 2 million people in the United States visit a physician each year for rotator cuff tears alone. The 2026 SER Annual Report includes implant component-level data for the first time, providing more detailed insights into treatment patterns and outcomes. AAOS leaders state that support from partners such as Enovis helps expand data collection, improve data quality, and strengthen registries as resources for clinicians seeking to enhance patient care.
Enovis (NYSE: ENOV) has entered into a binding offer to acquire French-based eCential Robotics, a developer of enabling technologies and surgical robotics. After completion of required information and consultation with eCential’s works council, the parties expect to sign a definitive purchase agreement, with closing targeted for the fourth quarter of 2026, subject to regulatory approvals.
eCential Robotics brings a modular, scalable platform for robotic-assisted surgery, including its FDA 510(k)-cleared Op.n® Spine Navigation and Robotic Guidance Platform. According to the companies, the deal would add robotic automation to Enovis’ ASTRA™ ecosystem and complement its ARVIS® Augmented Reality System, broadening Enovis’ surgical enabling technology portfolio.
Enovis (NYSE: ENOV) has entered into a binding offer to acquire eCential Robotics, a developer of enabling technologies and surgical robotics, to expand its ASTRA™ platform with robotic automation. The deal values eCential Robotics at an upfront enterprise value of €155 million, with approximately €176 million in cash to be paid to shareholders at closing, plus up to €35 million in contingent consideration tied to milestones.
The transaction is expected to close by year-end 2026, funded with Enovis’ cash and its existing revolving credit facility, and remains subject to regulatory approvals and French works council procedures. Enovis anticipates around 150 basis points of deal-related dilution to adjusted EBITDA margin in 2027, partially offset by 50 basis points of underlying improvement, resulting in a 100 basis point headwind. Free cash flow conversion is expected to rise to 50% in 2027, exceeding $100 million, with further improvement projected for 2028 and 2029. The acquisition will also establish a robotics center of excellence in Grenoble, France.
Enovis (NYSE: ENOV) announced it will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at Encore Boston Harbor. CEO Damien McDonald and CFO Ben Berry will join a fireside chat at 1:30 p.m. Eastern Time. A live audio webcast and replay will be accessible through the company’s website under the Investors > Events and Presentations section.
Enovis (NYSE: ENOV) reported second-quarter 2026 net sales of $582.8 million, up 3% reported and 5% organic versus 2025, with Reconstructive sales up 8% reported and 6% organic, and P&R down 1% reported but up 3% organic. Gross margin rose to 61.6%, and operating income improved to $17.4 million (3.0% margin) from a prior-year loss. The company recorded a small GAAP net loss of $1.0 million (‑0.2% margin) or $(0.02) per diluted share, while adjusted net income from continuing operations was $52.2 million and adjusted EPS was $0.90. Adjusted EBITDA reached $104 million, or 17.9% of sales. Enovis reaffirmed 2026 guidance for revenue of $2.31–$2.37 billion (4–6% organic growth), adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and full‑year free cash flow conversion of at least 25%.
Enovis (NYSE: ENOV) will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6, 2026 at 8:30 a.m. Eastern Time. An earnings press release will be issued earlier that morning, and investors can access the webcast, presentation, and same-day replay through the Investors section of the Enovis website.
Enovis (NYSE: ENOV) launched CT-RevitL in the United States on July 13, 2026, as a next-generation veterinary photobiomodulation (PBM) laser therapy system from its Companion Animal Health business. According to Enovis, CT-RevitL is built on more than 150 published PBM studies.
The system is designed to deliver deeper, faster and more consistent therapeutic outcomes for animals, aided by Companion’s new COMPASS intelligent treatment guidance technology, which calibrates dosing and reduces treatment variability. Enovis positions CT-RevitL to support drug-sparing pain management, practice efficiency, recurring non-drug care demand and differentiation for veterinary practices across a wide range of conditions.
Enovis (NYSE:ENOV) launched the DonJoy Spinamic Hybrid Scoliosis Brace, a first-of-its-kind hybrid device for adolescent idiopathic scoliosis. It combines rigid corrective elements with a breathable, adjustable vest to support in-brace curve correction while aiming to improve comfort and compliance.
Spinamic, supported by published clinical evidence for preventing curve progression in AIS, uses an adjustable three-point pressure system and comes in 10 off-the-shelf sizes. It allows fitting, in-brace X-ray, and adjustment in a single visit. The brace is now available in the United States, with regulatory clearance being pursued globally.
Enovis (NYSE: ENOV) reported first-quarter 2026 net sales of $589 million, up 5% reported and 3% organic year-over-year. Recon sales grew 11% reported (6% organic); P&R was flat reported (1% organic). Enovis reported a first-quarter net loss of $8 million and adjusted EBITDA of $104 million (17.6% margin). The company reaffirmed 2026 guidance: revenue of $2.31–2.37 billion, adjusted EBITDA of $425–435 million, adjusted EPS of $3.52–3.73, and free cash flow conversion of 25% or higher.